Douglas A. Arenberg - Concepedia

Author

Douglas A. Arenberg

Also Known As

Arenberg, Douglas, Arenberg, Douglas A., Bentham Science Publisher D.A. Arenberg, Chen, Alexander C., D A Arenberg, D ARENBERG, D Arenberg, D. A. Arenberg, D. Arenberg, D.A. Arenberg

224

Publications

14K

Citations

H-Index

123

Concepts

All Affiliations

University of Michigan Michigan Medicine Cleveland Clinic Pulmonary and Critical Care Associates VA Ann Arbor Healthcare System

About

Douglas A. Arenberg is an author at University of Michigan specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	48	7K
2	Health Sciences	10	10	880
3	Public Health	5	5	365
4	Social Sciences	2	2	99
5	Education	1	1	70

Douglas A. Arenberg

Publications

12.6K

Citations

H-Index

Page 1

	Year	Citations
The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis Robert M. Strieter, Peter J. Polverini, Steven L. Kunkel, Journal of Biological Chemistry	1995	1.2K
CXC chemokines in angiogenesis John A. Belperio, Michael P. Keane, Douglas A. Arenberg, Journal of Leukocyte Biology InflammationCytokineAngiogenesisSignal TransductionCxc Chemokines	2000	806
Treatment of Stage III Non-small Cell Lung Cancer Nithya Ramnath, Thomas J. Dilling, Loren J. Harris, CHEST Journal MedicineCancer TreatmentPulmonary BlastomaOncologyRadiation Oncology	2013	446
Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. Douglas A. Arenberg, S L Kunkel, Peter J. Polverini, Journal of Clinical Investigation Lung InflammationImmunologyPathologyImmunotherapyCancer Biology	1996	401
Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study Erik Folch, Michael A. Pritchett, Michael Nead, Journal of Thoracic Oncology	2018	393
The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis Michael P. Keane, Douglas A. Arenberg, Joseph P. Lynch, The Journal of Immunology	1997	384
Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. Douglas A. Arenberg, S L Kunkel, Peter J. Polverini, The Journal of Experimental Medicine AngiogenesisInterferon-gamma-inducible Protein 10Nsclc Tumor GrowthMedicineTumor Growth	1996	351
Final toxicity results of a radiation-dose escalation study in patients with non–small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis Feng‐Ming Kong, James A. Hayman, Kent A. Griffith, International Journal of Radiation OncologyBiologyPhysics Radiation MedicineHealth SciencesRadiation TherapyMedicineRadiation Pneumonitis	2006	335
Interferon γ-Inducible Protein-10 (IP-10), a Member of the C-X-C Chemokine Family, Is an Inhibitor of Angiogenesis Robert M. Strieter, Steven L. Kunkel, Douglas A. Arenberg, Biochemical and Biophysical Research Communications InflammationCytokineAngiogenesisImmunologyInterferon γ-Inducible Protein-10	1995	289
Differential Protein Expression Profiling by iTRAQ−2DLC−MS/MS of Lung Cancer Cells Undergoing Epithelial-Mesenchymal Transition Reveals a Migratory/Invasive Phenotype Venkateshwar G. Keshamouni, George Michailidis, Catherine S. Grasso, Journal of Proteome Research	2006	278

Page 1